GlassScriptPhysician profile
Gopal Narasimhan
NPI 1174732663
$58,294.76
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $2,399 · 2021: $12K · 2022: $8,313 · 2023: $6,097 · 2024: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,375 · Food and Beverage: $703 · Travel and Lodging: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,375.00 |
| Food and Beverage | $703.41 |
| Travel and Lodging | $567.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23,632.10 | 2019-2024 | Xifaxan, Trulance, Uceris |
| Abbvie INC. | $22,031.51 | 2019-2023 | |
| Allergan, INC. | $12,220.45 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $159.71 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $78.11 | 2021-2022 | |
| Ardelyx, INC. | $51.34 | 2023-2024 | Ibsrela |
| Cumberland Pharmaceuticals, INC. | $34.71 | 2019 | |
| Celgene Corporation | $25.01 | 2021 | |
| Daiichi Sankyo INC. | $22.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.72 | 2021 | |
| Gilead Sciences, INC. | $18.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopal Narasimhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.